ONCY: Oncolytics Biotech Inc insider trading, 5% holders and institutional ownership
From public SEC filings: open-market insider purchases and sales (Form 4, last 180 days), holders of 5% or more (Schedules 13D and 13G) and institutional ownership (Form 13F). Insider and 5% data delayed 48 hours.
Insider trading
0 open-market buys totaling - and 0 sales totaling - in the last 180 days.
Institutional ownership (Q2 2026)
75 institutions reported holding $3.58M of Oncolytics Biotech Inc on Form 13F (2 the quarter before). 72 opened a new position and 1 sold out. Shares held by institutions: +340%.
| Largest holders | Shares | Value |
|---|---|---|
| MARSHALL WACE, LLP | 745,350 | $708K |
| XTX Topco Ltd | 260,903 | $248K |
| SEEDS INVESTOR LLC | 258,306 | $245K |
| INTERNATIONAL ASSETS INVESTMENT MANAGEMENT, LLC | 201,260 | $181K |
| Connective Capital Management, LLC | 185,712 | $176K |
| GOLDMAN SACHS GROUP INC | 169,898 | $161K |
| TOCQUEVILLE ASSET MANAGEMENT L.P. | 147,000 | $140K |
| Everhart Financial Group, Inc. | 140,899 | $134K |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 134,129 | $127K |
| PFG Investments, LLC | 128,300 | $122K |
Clinical trial readouts
2 Phase 2 or 3 trials by Oncolytics Biotech Inc with a primary completion date in the last 90 days or the next 12 months and no results posted yet, from ClinicalTrials.gov. (est.) = company estimate.
| Primary completion | Drug | Condition | Phase | Patients | Status | Trial |
|---|---|---|---|---|---|---|
| 2027-07-30 (est.) | Pelareorep | Anal Cancer Metastatic | Phase 1/2 | 122 | Enrollment complete | NCT07280377 |
| 2027-08-30 (est.) | Bevacizumab | Ras-mutated Metastatic Colorectal Cancer | Phase 2 | 60 | Recruiting | NCT07446322 |
Get new insider and activist filings the morning after: daily alerts. Not investment advice.